Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-dose Escalation, Multiple-dose Escalation, and Food Effect Study of RPT193 in Healthy Subjects and Patients With Moderate to Severe Atopic Dermatitis

NCT04271514 is registered in ClinicalTrials.gov with RAPT Therapeutics, Inc. as lead sponsor.

NCT NCT04271514
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04271514 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-dose Escalation, Multiple-dose Escalation, and Food Effect Study of RPT193 in Healthy Subjects and Patients With Moderate to Severe Atopic Dermatitis
Lead sponsor
RAPT Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 12, 2019
Completion date
April 26, 2021
Enrollment
103 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis